Cabozantinib improves survival in patients with advanced kidney cancer: Results from the METEOR trial

Sunday, September 27, 2015 - 17:00 in Health & Medicine

Patients with advanced kidney cancer live for nearly twice as long without their disease progressing if they are treated with cabozantinib, a drug that inhibits the action of tyrosine kinases -- enzymes that function as an 'on' or 'off' switch in many cellular processes, including cancer. The research will be presented in the presidential session of the 2015 European Cancer Congress on Saturday.

Read the whole article on Science Daily

More from Science Daily

Latest Science Newsletter

Get the latest and most popular science news articles of the week in your Inbox! It's free!

Check out our next project, Biology.Net